Gogoro Inc vs Eli Lilly And Co — how do they compare? Gogoro Inc trades at $3.86 (market cap $77.38M), while Eli Lilly And Co trades at $1,180.1 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 13310.9× Gogoro Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.
| GGR | LLY | |
|---|---|---|
Market Cap | $77.38M | $1.03T |
Sector | Technology | Health |
52-Week High | $7.89 | $1.24K |
52-Week Low | $2.74 | $625.65 |
Enterprise Value | $379.83M | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →